Format

Send to

Choose Destination
Nucleic Acids Res. 2018 Jan 4;46(D1):D1137-D1143. doi: 10.1093/nar/gkx1088.

SuperDRUG2: a one stop resource for approved/marketed drugs.

Author information

1
Structural Bioinformatics Group, Experimental and Clinical Research Center (ECRC), Charité - University Medicine Berlin, Berlin, Germany.
2
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
3
BB3R - Berlin Brandenburg 3R Graduate School, Freie Universitaät Berlin, Berlin, Germany.
4
Structural Bioinformatics Group, Institute for Physiology, Charité - University Medicine Berlin, Berlin, Germany.
5
China Scholarship Council (CSC), China.

Abstract

Regular monitoring of drug regulatory agency web sites and similar resources for information on new drug approvals and changes to legal status of marketed drugs is impractical. It requires navigation through several resources to find complete information about a drug as none of the publicly accessible drug databases provide all features essential to complement in silico drug discovery. Here, we propose SuperDRUG2 (http://cheminfo.charite.de/superdrug2) as a comprehensive knowledge-base of approved and marketed drugs. We provide the largest collection of drugs (containing 4587 active pharmaceutical ingredients) which include small molecules, biological products and other drugs. The database is intended to serve as a one-stop resource providing data on: chemical structures, regulatory details, indications, drug targets, side-effects, physicochemical properties, pharmacokinetics and drug-drug interactions. We provide a 3D-superposition feature that facilitates estimation of the fit of a drug in the active site of a target with a known ligand bound to it. Apart from multiple other search options, we introduced pharmacokinetics simulation as a unique feature that allows users to visualise the 'plasma concentration versus time' profile for a given dose of drug with few other adjustable parameters to simulate the kinetics in a healthy individual and poor or extensive metabolisers.

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center